Patents by Inventor Sam Malekiani

Sam Malekiani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20250034145
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: February 29, 2024
    Publication date: January 30, 2025
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20240199617
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: July 13, 2023
    Publication date: June 20, 2024
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 11542264
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: January 3, 2023
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210403474
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: February 12, 2021
    Publication date: December 30, 2021
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10752633
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: August 25, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200131190
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 30, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10584131
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: March 10, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200039987
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser